Myeloma UK Clinical Trials Network (CTN) success drives new patient-focused research grant program called the UK Myeloma Research Alliance—Myeloma UK Concept and Access Research Program (UKMRA-Myeloma UK CARP) sponsored by Myeloma UK.
Who is Myeloma UK?
Established in 1997 in a quest to find a cure to myeloma, Myeloma UK purports to be the only organization in the UK dealing exclusively with myeloma. Dedicated to myeloma patients, they seek to ensure they get access to the right treatment at the right time. Dedicated to the mission to improve standards of treatment and care through research, education and raising awareness of myeloma. Myeloma UK receives no government funding—relying almost entirely on voluntary donations and fundraising.
Results since 1997
- As a consequence of collaborative engagement, they have established 34 Clinical Trial centers across the UK recruiting hundreds of patients to innovative trials
- Worked to improve access to drugs and treatments on the NHS and influence health policy through the patient advocacy work
- Developed and maintained patient information publications
- Developed Myeloma Infoline and Ask the Nurse email service
- Fundraising leading to over 31.2 million pounds
A grant initiative building on the success of the 10 -year old Myeloma UK Clinical Trials Network. A key goal of Myeloma UK is to find answers through investments in investigations—, particularly clinical trials.
UKMRA-Myeloma UK CARP has been set up to offer grants to scientists or hospitals aiming to begin a Phase I or Phase II clinical trial. Under the program, proposed trials must address an unmet patient need, support access to treatment through the National Health Service (NHS), or generate proof-of-concept data for larger, later trials. Touted as the only initiative in the UK focused on the development of early-phase multiple myeloma trials, they also aim to put the UK at the forefront of myeloma research in support of patients in England, Wales, Scotland and Northern Ireland.
A Collaborative Model
The collaborative model combines Myeloma UK’s funding and patient insight with the experience and expertise of the University of Leeds Clinical Trials Research Unit and the UK Myeloma Research Alliance, a clinical research collaborative. The effort has been set up to assess and explore innovative study designs such as adaptive trials, where investigators have the flexibility to adjust treatments based on patient responses reports Mary Chapman of Myeloma Research News.
University of Leeds Clinical Trials Research Unit
A leading UK academic clinical trials unit, their Clinical Trials Research Unit (CTRU) spans three divisions which include a broad range of diseases and treatments with an emphasis on trial design, conduct, and analysis.
Myeloma Clinical Trials Network
Formed in 2009, the collaborative CTN has resulted in nine early phase clinical trials at more than 40 sites, involving approximately 700 patients.